<table className="table">
  <caption><p>
    Recommendations for Prostate Cancer Screening</p>
  </caption>
  <thead>
    <tr>
      <th rowSpan="1" colSpan="1"><p>
        Expert Group</p>
      </th>
      <th rowSpan="1" colSpan="1"><p>
        Recommendation</p>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr className="group_1-1 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        American Cancer Society (2010)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Age 40-44 y: Engage men at higher risk (≥2 first-degree relatives with prostate cancer before age 65 y) in shared decision making</p><p>
        Age 45-49 y: Engage men at high risk (African American race or first-degree relative with prostate cancer before age 65 y) in shared decision making</p><p>
        Age ≥50 y with life expectancy ≥10 y: Engage in shared decision making</p>
      </td>
    </tr>
    <tr className="group_1-2 row-even">
      <td rowSpan="1" colSpan="1"><p>
        American College of Physicians (2013)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Age 50-69 y: Inform men about the limited potential benefits and substantial harms of screening for prostate cancer; test only men who request screening after informed discussion</p><p>
        Age &lt;50 y, &gt;69 y, or with a life expectancy &lt;10 y: Recommend against screening</p>
      </td>
    </tr>
    <tr className="group_1-3 row-odd">
      <td rowSpan="1" colSpan="1"><p>
        American Urological Association (2013; reviewed and confirmed 2018)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Clinicians should engage in shared decision making with patients in whom prostate cancer screening would be appropriate and proceed when consistent with patient preferences</p><p>
        Age 40-45 y: Offer screening to men at increased risk (Black ancestry, strong family history of prostate cancer, or presence of germline variants)</p><p>
        Age 45-50 y: May begin screening in average-risk individuals</p><p>
        Age 50-69 y: Offer regular screening every 2-4 y</p>
      </td>
    </tr>
    <tr className="group_1-4 row-even">
      <td rowSpan="1" colSpan="1"><p>
        U.S. Preventive Services Task Force (2018)</p>
      </td>
      <td rowSpan="1" colSpan="1"><p>
        Age 55-69 y: Discuss potential benefits and harms of PSA-based screening for prostate cancer and individualize decision making by incorporating the patient's values and preferences</p><p>
        Age ≥70 y: Recommend against PSA-based screening</p>
      </td>
    </tr>
  </tbody>
</table>